Medicus Pharma Reports Positive Expanded Phase 2 Skinject Study Results

May 6, 2026

Medicus Pharma (NASDAQ: MDCX) has reported positive expanded dataset results from its Phase 2 Skinject study, evaluating a doxorubicin microneedle array treatment for nodular basal cell carcinoma, the most common form of skin cancer. The analysis demonstrated a positive dose response, further strengthening the therapy’s clinical profile.

The new findings provide additional biological, histologic, and safety insights that support future discussions with the FDA and reinforce consistency with earlier Phase 1 data. Medicus continues to position Skinject as a potentially disruptive, minimally invasive treatment option in dermatologic oncology.

#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#Oncology
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#Dermatology
#Innovation
#JaneKing
#NewsOut